Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 200.24

+2.1%

Jan 7 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Machaon who wrote (24428)	8/12/1998 10:33:00 PM
From: Henry Niman	of 32384

From June 4, 1998 BARS report: This deal was primarily driven by Seragen's lead compound, Ontak, which is under FDA consideration to treat cutaneous T-cell lymphoma (CTCL). - Seragen has spent over $200 million in the development of this technology. - Eli Lilly has spent another $20 million on Ontak. - We believe that Ontak is a late stage product that fits well in Ligand's cancer franchise, specifically to treat CTCL.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next